Form 4: BioSig Technologies Director Acquires Shares in Lieu of Cash Compensation

Director Steven Eric Abelman acquired 23,345 shares of BioSig Technologies common stock in lieu of cash compensation for board fees.

Summary

• On April 24, 2025, Steven Eric Abelman, a director of BioSig Technologies, Inc., acquired 23,345 shares of common stock.
• The shares were granted under the company's 2023 Equity Incentive Plan in lieu of cash for Q4 2024 and Q1 2025 board fees.
• The shares were fully vested as of the date of grant, April 24, 2025.
• The closing price of BioSig Technologies' stock on the date of grant was $0.84 per share.
• Following the transaction, Abelman directly owns 103,345 shares of BioSig Technologies common stock.

Sentiment

Score: 6

Explanation: Neutral sentiment. A director taking shares in lieu of cash is generally a positive sign, but the overall impact is likely minimal.

Positives

• A director taking equity in lieu of cash demonstrates confidence in the company's future prospects.

Industry Context

Directors accepting stock in lieu of cash compensation is a common practice, especially for smaller companies, to conserve cash and align director interests with shareholder value.

Stakeholder Impact

• Shareholders may view the director's acceptance of stock as a positive signal.

Key Dates

Keywords

BioSig Technologies, Director, Share Acquisition, Equity Incentive Plan, Common Stock, Compensation, BSGM